KOD Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -- compared to Kodiak Sciences's net margin of -101870.49%. Kodiak Sciences's return on equity of -- beat Editas Medicine's return on equity of -74.59%.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -33%. On the other hand Editas Medicine has an analysts' consensus of $8.50 which suggests that it could grow by 188.71%. Given that Editas Medicine has higher upside potential than Kodiak Sciences, analysts believe Editas Medicine is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Editas Medicine has a beta of 1.947, suggesting its more volatile than the S&P 500 by 94.725%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Editas Medicine quarterly revenues of $61K. Kodiak Sciences's net income of -$43.9M is higher than Editas Medicine's net income of -$62.1M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 1.69x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Kodiak Sciences's net margin of 25.23%. Kodiak Sciences's return on equity of -- beat Pfizer's return on equity of 4.63%.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -33%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.1%. Given that Pfizer has higher upside potential than Kodiak Sciences, analysts believe Pfizer is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.33% to investors and pays a quarterly dividend of $0.42 per share. Kodiak Sciences pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Kodiak Sciences's net income of -$43.9M is lower than Pfizer's net income of $4.5B. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 2.54x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Kodiak Sciences's net margin of 36.03%. Kodiak Sciences's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -33%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,063.08 which suggests that it could grow by 47.84%. Given that Regeneron Pharmaceuticals has higher upside potential than Kodiak Sciences, analysts believe Regeneron Pharmaceuticals is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Kodiak Sciences's net income of -$43.9M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 5.92x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to Kodiak Sciences's net margin of -63.65%. Kodiak Sciences's return on equity of -- beat Revance Therapeutics's return on equity of --.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -33%. On the other hand Revance Therapeutics has an analysts' consensus of $8.21 which suggests that it could grow by 151.22%. Given that Revance Therapeutics has higher upside potential than Kodiak Sciences, analysts believe Revance Therapeutics is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.274%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Kodiak Sciences's net income of -$43.9M is lower than Revance Therapeutics's net income of -$38.1M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 1.14x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.